A new paper in Nature Reviews Microbiology sets a high standard for thinking about the dynamics and strategies of commercialization of a class of novel diagnostics.
It's a case study based on an active area of innovation, antibiotic sensitivity testing. However, I'd emphasize the the scope and logic of the thinking
applies to other kinds of diagnostics (or even other kinds of medical innovation) as well.
- Nature Reviews open access paper here.
- Nature Reviews tweet here.
- Blog by coauthor John Rex here.